Table 3

Information on irinotecan chemotherapy

Leukopenia (grade 4) and/or diarrhea (grade 3 or worse)a
Experienced (n = 26)Not experienced (n = 92)P
Regimens0.015b
Irinotecan alone3 (12%)32 (35%)
Irinotecan and platinum13 (50%)45 (49%)
Irinotecan and other anticancer drugs10 (38%)15 (16%)
Concurrent radiotherapy1 (4%)8 (9%)>0.2c
Intended schedule0.059b
Weekly (days 1, 8, and 15)15 (72%)62 (67%)
Every 3 or 4 weeks8 (31%)11 (12%)
Twice every 4 weeks3 (12%)19 (21%)
Intended irinotecan dosage for each infusion (mg/m2)>0.2b
<609 (35%)18 (20%)
608 (31%)34 (37%)
>609 (35%)40 (43%)
Total actual dosage (mg/m2)0.010b
<30015 (58%)24 (26%)
301–6007 (27%)46 (50%)
>6004 (15%)22 (24%)
Use of granulocyte colony- stimulating factor (days)<0.001b
05 (19%)61 (66%)
1–1411 (42%)13 (14%)
≥1510 (38%)18 (26%)
Use of loperamide hydrochloride (days)0.002b
04 (15%)51 (55%)
1–715 (58%)28 (30%)
≥87 (27%)13 (14%)
Objective response>0.2b
Complete or partial11 (48%)31 (39%)
Stable disease8 (35%)36 (45%)
Progressive disease4 (17%)13 (16%)
Not measurable312
  • a Japan Society for Cancer Therapy criteria.

  • b χ2 test.

  • c Fisher’s exact test.